Article | May 26, 2021

Building A Robust Cell And Gene Therapy Supply Chain

Source: Invetech

By Travis Ott, Senior Manager, Single-Use Set (SUS) & Supply Chain, Invetech

Invetech single Use

Current supply chains support distinct automated CGT manufacturing elements when they are well-characterized and integrated into commercial manufacturing. As cell therapies develop and become more commercialized, manufacturers must adopt a sophisticated supply chain that provides the necessary materials and technologies to support therapeutic development.

Once a CGT manufacturing process is registered with regulatory authorities, it’s difficult and expensive to change it. CGT manufacturers must ensure their supply chain can support the manufacturing process.

In this blog we review how CGT manufacturers can identify suppliers, avoid shortages and incorporate cost savings to build a successful supply chain.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: